MEDIO Stock Overview

Develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. More details

MEDIO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	4/6
Financial Health	6/6
Dividends	3/6

Rewards

Earnings are forecast to grow 4.99% per year

Earnings grew by 10.5% over the past year

Risk Analysis

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Medistim ASA Competitors

NIOX Group

AIM:NIOX

UK£238.8m

EKF Diagnostics Holdings

AIM:EKF

UK£120.7m

Smith & Nephew

LSE:SN.

UK£8.6b

Advanced Medical Solutions Group

AIM:AMS

UK£413.9m

Price History & Performance

Summary of share price highs, lows and changes for Medistim
Historical stock prices
Current Share Price	NOK 246.75
52 Week High	NOK 305.00
52 Week Low	NOK 246.75
Beta	0.83
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	48.65%
5 Year Change	220.45%
Change since IPO	411.93%

Recent updates

Shareholder Returns

	MEDIO	GB Medical Equipment	GB Market
7D	0%	-0.2%	0.6%
1Y	n/a	-10.7%	4.6%

Return vs Industry: Insufficient data to determine how MEDIO performed against the UK Medical Equipment industry.

Return vs Market: Insufficient data to determine how MEDIO performed against the UK Market.

Price Volatility

Is MEDIO's price volatile compared to industry and market?
MEDIO volatility
MEDIO Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.5%

Stable Share Price: MEDIO has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine MEDIO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1984	117	Kari Krogstad	www.medistim.com

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis.

Medistim ASA Fundamentals Summary

How do Medistim's earnings and revenue compare to its market cap?
MEDIO fundamental statistics
Market cap	NOK 4.69b
Earnings (TTM)	NOK 97.61m
Revenue (TTM)	NOK 458.69m

48.1x

P/E Ratio

10.2x

P/S Ratio

Is MEDIO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MEDIO income statement (TTM)
Revenue	NOK 458.69m
Cost of Revenue	NOK 101.60m
Gross Profit	NOK 357.09m
Other Expenses	NOK 259.48m
Earnings	NOK 97.61m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	5.35
Gross Margin	77.85%
Net Profit Margin	21.28%
Debt/Equity Ratio	0%

How did MEDIO perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

70%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/11/16 23:59
End of Day Share Price	2022/08/19 00:00
Earnings	2022/09/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medistim ASA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Magnus Granerød	Beringer Finance AB
Karl Norén	Danske Bank
Simen Mortensen	DNB Markets